Information from the Editor of ActaDV
Excerpta from Volume 96 of ActaDV
Anders Vahlquist, Editor-in-Chief of Acta Dermato-Venereologica
Department of Dermato-Venereology, Uppsala University Hospital, Uppsala, Sweden. E-mail: anders. vahlquist @ medsci. uu. se
In an attempt to illustrate the width and novelty of clinical and experimental research presented in Acta Dermato Venereologica, the Editor-in-Chief Anders Vahlquist has selected 20 out of nearly 250 publications in 2016. Here, a short commentary on each of the papers from 5 different research areas is presented( in alphabetical order).
Cancer
The first paper in volume 96 of ActaDV is a review by Professor Irene Leigh and her co-workers in London and Dundee( 1), describing the promise of genomics in dissecting various disease mechanisms in squamous cell carcinoma( SCC), with the ultimate goal of finding new treatment targets( Fig. 1). Among the many possible therapies, inhibitors of various epidermal growth factors and immunomodulatory drugs are discussed in some depth.
In another report, Professor Nicole Basset-Seguin and her team in Paris present the results of photodynamic therapy( PDT) in
105 cases of Bowen’ s disease, focusing on the relapse rates of invasive cancers( 2). SCC occurred post-PDT in 16 out of the treated fields, but whether or not these“ treatment failures” originated from microscopic nests of pre-existing SCC within the Bowenoid lesions before PDT is not known. However, the results remind us about the importance of careful follow-ups of PDT-treated Bowen’ s disease, especially in immunosuppressed individuals.
Immunosuppression is also a factor of importance in the context of basal cell carcinoma( BCC). In a Danish study, Omland et al. examine the role of regulatory T cells( T-regs)
Fig. 1. Summary of aetiology factors in cutaneous squamous cell carcinoma( SCC). AK: actinic keratosis.( From ref 1 with permission from Acta Derm Venereol).
Forum for Nord Derm Ven 2016, Vol. 21, No. 4 89